<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H5B1A3605B1EF4317807969D127AC5C47" public-private="public" key="H" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4005 IH: Naloxone Affordability Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-06-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session> 
<legis-num display="yes">H. R. 4005</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action display="yes"> 
<action-date date="20230612">June 12, 2023</action-date> 
<action-desc><sponsor name-id="K000382">Ms. Kuster</sponsor> (for herself, <cosponsor name-id="B001303">Ms. Blunt Rochester</cosponsor>, and <cosponsor name-id="C001119">Ms. Craig</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title display="yes">To direct the Comptroller General of the United States to conduct a study on naloxone access.</official-title> 
</form> 
<legis-body id="HE85503C872F244E7958D164055B70D33" style="OLC"> 
<section id="H6E4CB14F98C64FABBE60014C0F1C487C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Naloxone Affordability Act of 2023</short-title></quote>.</text> </section> <section id="H550C6BC1F6F54DCC97501089CEE7B939"><enum>2.</enum><header>Study on naloxone access</header> <subsection id="H762321E3B1644E68B017D7807F289ECB"><enum>(a)</enum><header>In general</header><text>The Comptroller General of the United States shall conduct a study on actions that may be taken to ensure appropriate access and affordability of naloxone for individuals seeking to purchase naloxone. Such study shall address what is known about—</text> 
<paragraph id="HB26F508E3833496A89E53E88A6E16EC5"><enum>(1)</enum><text display-inline="yes-display-inline">coverage of naloxone (in any available form), including whether naloxone can be covered as an over-the-counter drug under a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-91">42 U.S.C. 300gg–91</external-xref>)) or for individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395 et seq.</external-xref>) or receiving medical assistance under a State plan under title XIX of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396 et seq.</external-xref>) or a waiver of such plan;</text></paragraph> <paragraph id="HC5C1AF34B4544F25A6B584A6AD2F2F96"><enum>(2)</enum><text>the out-of-pocket cost to consumers purchasing naloxone—</text> 
<subparagraph id="H0D10ADF681ED4B88B8E185BB9E1DA1C7"><enum>(A)</enum><text>with a prescription, with and without coverage under any such plan or coverage;</text></subparagraph> <subparagraph id="H60CFF4A3596F4EE1B1D0952BCDF1A77D"><enum>(B)</enum><text>over the counter, with and without coverage under any such plan or coverage; and</text></subparagraph> 
<subparagraph id="HD0D9E7ED25B8415EA6D204B11726E39E"><enum>(C)</enum><text>pursuant to a standing order; and</text></subparagraph></paragraph> <paragraph id="H9218798E63DF413FB8A6D3C288F42419"><enum>(3)</enum><text>other factors impacting coverage, including barriers in covering naloxone as an over-the-counter drug, the relative net costs of naloxone when purchased over the counter without insurance coverage compared to when purchased with a prescription and covered under a group health plan or health insurance coverage, and the availability of naloxone purchased and distributed through public health entities.</text></paragraph></subsection> 
<subsection id="H43C13A53F4504CD59C650078A0A50679"><enum>(b)</enum><header>Report</header><text>Not later than 2 years after the date of the enactment of this Act, the Comptroller General of the United States shall submit to Congress a report that contains the findings of the study conducted under subsection (a).</text></subsection></section> </legis-body> </bill> 

